Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec 1;130(12):6232-6234.
doi: 10.1172/JCI143466.

What are protective antibody responses to pandemic SARS-CoV-2?

Jeffrey P Henderson
Comment

What are protective antibody responses to pandemic SARS-CoV-2?

Jeffrey P Henderson. J Clin Invest. .

Abstract

Human antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hold intense interest, with research efforts directed at optimizing antibody-based interventions and monitoring immune status. By relating individual variations in antibody response to coronavirus disease 2019 (COVID-19) severity, beneficial antiviral immune responses may be identified in detail. In this issue of the JCI, Secchi and collaborators describe antibody response profiles in 509 patients with COVID-19 from Italy during the 2020 pandemic. The research team found that multiple antibody types to multiple SARS-CoV-2 antigens developed over four weeks. Notably, IgG against the spike receptor binding domain (RBD) was predictive of survival and IgA against the viral spike protein (S protein) associated with rapid virologic clearance. These results may help guide selection of convalescent plasma, hyperimmune products, monoclonal antibodies, and vaccine strategies for COVID-19.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: JPH laboratory research on COVID-19 was supported by an unrestricted financial gift from Octapharma.

Comment on

References

    1. Bloch EM, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757–2765. doi: 10.1172/JCI138745. - DOI - PMC - PubMed
    1. Joyner MJ, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130(9):4791–4797. doi: 10.1172/JCI140200. - DOI - PMC - PubMed
    1. doi: 10.1101/2020.07.29.20162917. Joyner MJ, et al. Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy [preprint]. Posted on medRxiv August 28, 2020. - DOI
    1. doi: 10.1101/2020.08.12.20169359. Joyner MJ, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience [preprint]. Posted on medRxiv August 12, 2020. - DOI
    1. Salazar E, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020;190(11):2290–2303. doi: 10.1016/j.ajpath.2020.08.001. - DOI - PMC - PubMed

Publication types

Substances